GlassScriptPhysician profile
Juan Carden
NPI 1639101868
$2,130.37
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,106 · 2020: $24.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $203.17 | 2019 | |
| Incyte Corporation | $183.77 | 2019 | |
| Merck Sharp & Dohme LLC | $163.07 | 2019 | |
| Celgene Corporation | $155.27 | 2019 | |
| Genzyme Corporation | $148.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $143.99 | 2019 | |
| Genentech USA, INC. | $128.91 | 2019 | |
| Janssen Biotech, INC. | $120.29 | 2019 | |
| Pfizer INC. | $118.31 | 2019 | |
| Amgen INC. | $107.53 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $87.34 | 2019 | |
| Mylan Institutional INC. | $69.23 | 2019 | |
| Gilead Sciences, INC. | $66.59 | 2019 | |
| Exelixis INC. | $63.69 | 2019-2020 | |
| Lilly USA, LLC | $61.79 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.01 | 2019 | |
| Astellas Pharma US INC | $38.27 | 2019 | |
| Puma Biotechnology, INC. | $28.42 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $26.59 | 2019 | |
| Taiho Oncology, INC. | $24.27 | 2019 | |
| Amag Pharmaceuticals, INC. | $21.81 | 2019 | |
| Eisai INC. | $21.77 | 2019 | |
| Verastem, INC. | $21.27 | 2019 | |
| Abbvie INC. | $19.29 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.02 | 2019 | |
| Dova Pharmaceuticals | $11.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Carden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.